■胸部NUT癌是一种极为罕见的肿瘤,其特征是NUTM1基因与溴结构域遗传家族成员之间的易位。由于肿瘤的稀有性,标准化治疗指南尚未建立.已经使用了几种化疗剂,取得了有限的成功。由于对治疗的耐药性迅速发展。Pembrolizumab,一种抗程序性死亡-1抗体,已越来越多地用于非小细胞肺癌。因此,派姆单抗可能对治疗NUT癌有益。
■在本文中,我们讨论了一例24岁男性患者,他因一项无关的计算机断层扫描偶然发现肿块而被转诊至我们中心.NUT癌伴骨转移的形态学和免疫组织化学特征高度可疑。病人接受了卡铂治疗,紫杉醇,和pembrolizumab作为一线治疗。患者随后进展,并开始根据Ewing方案接受二线治疗。20个月后,质量继续增长,患者开始服用多西他赛和吉西他滨,这是不成功的。在和病人讨论之后,他决定停止化疗,开始姑息治疗。
■NUT癌是一种侵袭性肿瘤,预后不良。治疗选择有限,派姆单抗似乎不影响肿瘤的临床结果。
■总的来说,pembrolizumab似乎不能改善NUT癌患者的预后。就作者所知,这是第二篇报道派姆单抗对NUT癌进展的影响的文章.
UNASSIGNED: NUT carcinoma of the thorax is an extremely rare neoplasm characterized by a translocation between the NUT M1 gene and members of the bromodomain genetic family. Due to the rarity of the neoplasm, standardized treatment guidelines have not yet been established. Several chemotherapeutic agents have been used with limited success, due to the rapid development of resistance to treatment. Pembrolizumab, an anti-programmed-death-1 antibody, has become increasingly used in non-small-cell lung carcinomas. Consequently, pembrolizumab may be beneficial in the treatment of NUT carcinoma.
UNASSIGNED: In this article, we discuss the
case of a 24-year-old man who was referred to our centre due to an incidental mass finding on an unrelated computed tomography scan. Morphological and immunohistochemical characteristics are highly suspicious of NUT carcinoma with bone metastasis. The patient was placed on carboplatin, paclitaxel, and pembrolizumab as first-line therapy. The patient later progressed and began receiving second-line treatment according to Ewing\'s protocol. 20 months later, the mass continued to grow, and the patient was started on docetaxel and gemcitabine, which was unsuccessful. After discussing with the patient, he decided to stop chemotherapy and begin palliative care.
UNASSIGNED: NUT carcinoma is an aggressive tumour with poor prognosis. Treatment options are limited and pembrolizumab does not seem to influence the clinical outcome of the neoplasm.
UNASSIGNED: Overall, pembrolizumab does not seem to improve the outcomes of NUT carcinoma patients. To the authors\' knowledge, this is the second article reporting the effects of pembrolizumab on the progression of NUT carcinoma.